3,7-dimethyl-1-(3-oxo-butyl)-3,7-dihydro-purine-2,6-dione | 10226-57-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 3,7-dimethyl-1-(3-oxo-butyl)-3,7-dihydro-purine-2,6-dione
• 英文别名: 3,7-Dimethyl-1-(3-oxobutyl)purine-2,6-dione
• CAS: 10226-57-0
• 化学式: C₁₁H₁₄N₄O₃
• 分子量: 250.257
• InChiKey: RQAOSCDWTLRAIN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  75.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  在 盐酸 、 甲醇 作用下， 生成 3,7-dimethyl-1-(3-oxo-butyl)-3,7-dihydro-purine-2,6-dione
  参考文献：
  名称：

  Potentiation of cADPR-Induced Ca²⁺-Release by Methylxanthine Analogues

  摘要：

  Caffeine and other methylxanthines are known to induce Ca2+-release from intracellular stores via the ryanodine receptor. In the present work, a range of caffeine analogues, in which methyl groups at the 1 and 7 positions were replaced with alkyl chains containing different functional groups (oxo, hydroxyl, propargyl, ester, and acids), were synthesized. These compounds were then screened for their ability to potentiate Ca2+-release induced by cADPR (an endogenous modulator of ryanodine receptors) in sea urchin egg homogenates. Two of the synthesized methylxanthines, 1,3-dimethyl-7-(7-hydroxyoctyl)xanthine (37) and 3-methyl-7-(7-oxooctyl)-1-propargylxanthine (66), were shown to be more potent than caffeine in potentiating cADPR-induced Ca2+-release, while 1,3-dimethyl-7-(5-ethylcarboxypentyl)xanthine (14) was shown to be more efficacious. The development of new methylxanthine analogues may lead to a better understanding of ryanodine receptor function and could possibly provide novel therapeutic agents.

  DOI：

  10.1021/jm980469t

文献信息

• NUCLEOSIDE DERIVATIVE FOR PREVENTING AND TREATING INFLAMMATION AND APPLICATION THEREOF
  申请人：West China Hospital of Sichuan University

  公开号：EP3950689A1

  公开（公告）日：2022-02-09

  The present invention provides a nucleoside derivative for preventing and treating inflammation and an application thereof in the preparation of a drug for preventing and treating inflammatory diseases. The nucleoside derivative for preventing and treating inflammation provided by the present invention can significantly ameliorate conditions of pancreatitis, hepatitis, arthritis and the like, ameliorate organ injury and inflammatory indexes, and have better effects than positive control drug, indometacin. Compared with the conventional anti-inflammatory drugs, aspirin, ibuprofen, indomethacin, phenylbutazone, diclofenac, piroxicam and glucocorticoids, the nucleoside derivative for preventing and treating inflammation provided by the present invention has the advantage of significantly fewer side effects.

  本发明提供了一种预防和治疗炎症的核苷衍生物及其在制备预防和治疗炎症疾病药物中的应用。本发明提供的预防和治疗炎症的核苷衍生物可显著改善胰腺炎、肝炎、关节炎等病症，改善器官损伤和炎症指标，效果优于阳性对照药物吲哚美辛。与传统的抗炎药物阿司匹林、布洛芬、吲哚美辛、苯丁酸、双氯芬酸、吡罗昔康和糖皮质激素相比，本发明提供的用于预防和治疗炎症的核苷衍生物具有副作用明显较小的优点。
• [EN] NUCLEOSIDE DERIVATIVE FOR PREVENTING AND TREATING INFLAMMATION AND APPLICATION THEREOF<br/>[FR] DÉRIVÉ NUCLÉOSIDIQUE DESTINÉ À LA PRÉVENTION ET AU TRAITEMENT D'UNE INFLAMMATION ET SON UTILISATION<br/>[ZH] 防治炎症反应的核苷类衍生物及其应用
  申请人：WEST CHINA HOSPITAL OF SICHUAN UNIV

  公开号：WO2020192665A1

  公开（公告）日：2020-10-01

  本发明提供了一类防治炎症反应的核苷类衍生物，以及该衍生物在制备防治炎症疾病的药物中的应用。本发明提供的防治炎症反应的核苷类衍生物能够明显改善胰腺炎、肝炎、关节炎等病情，改善器官受损和炎性指标，效果优于阳性对照药吲哚美辛。相比于传统抗炎药物阿司匹林、布洛芬、吲哚美辛、保泰松、双氯芬酸、吡罗昔康以及糖皮质激素，本发明提供的防治炎症反应的核苷类衍生物具有副作用明显更小的优势。
• KEHGASAVA, KADZUO;XIRAGIKI, MINEHXARU;VAGATSUMA, NAGATOSI;TSUMEHO, TSUNEH+
  作者：KEHGASAVA, KADZUO、XIRAGIKI, MINEHXARU、VAGATSUMA, NAGATOSI、TSUMEHO, TSUNEH+

  DOI：——

  日期：——